# RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

> **NCT01317615** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 49 (actual)

## Conditions studied

- Carcinoma, Large Cell
- Neuroendocrine Tumors

## Interventions

- **DRUG:** RAD001
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT01317615
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2016-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01317615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01317615, "RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01317615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*